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Review Article
Inflammatory myopathies are the largest group of potentially treatable myopathies in children and adults. They constitute a heterogeneous group of disorders that are best classified, on the basis of distinct clinicopatho-
logic features, in four subtypes: dermatomyositis, polymyositis, necrotizing auto-
immune myositis, and inclusion-body myositis (throughout this review, I use this 
term to refer specifically to sporadic inclusion-body myositis).1-6 A fifth subtype, 
termed overlap myositis, is also beginning to be recognized. The identification of 
the correct subtype and the distinction of these conditions from other diseases 
that have characteristics that mimic these conditions is fundamental, because each 
subtype has a different prognosis and response to therapies. This review reflects 
the current knowledge of these conditions, highlights how best to avoid erroneous 
diagnoses, describes the main clinicopathologic and immunologic features, and pro-
vides practical guidelines regarding therapies.
Gener a l Clinic a l Fe at ur es
Patients with inflammatory myopathies have increasing difficulty with tasks re-
quiring the use of proximal muscles, such as getting up from a chair, climbing steps, 
or lifting objects.1-6 Tasks requiring distal muscles, such as buttoning or holding 
objects, are affected early in inclusion-body myositis but only in advanced cases of 
polymyositis, dermatomyositis, and necrotizing autoimmune myositis. The ocular 
muscles are spared in all subtypes, but facial muscles are commonly affected in 
inclusion-body myositis.3 In all disease subtypes, neck-extensor and pharyngeal 
muscles can be involved, which results in difficulty holding up the head (head drop) 
or in dysphagia. In advanced and rare acute cases, the respiratory muscles can be 
affected. Muscle atrophy is detected early in inclusion-body myositis, with selective 
atrophy of the quadriceps and forearm muscles, but it develops in all subtypes if 
the weakness is severe and chronic. Myalgia and muscle tenderness may occur, 
especially in patients with the antisynthetase syndrome (see the Glossary),6,7 but if 
pain is severe and the weakness follows a “breakaway” pattern, in which the pa-
tient has difficulty sustaining effort, fasciitis or fibromyalgia should be ruled out.
Extramuscular manifestations may occur in all inflammatory myopathies, al-
though they occur in inclusion-body myositis only in rare cases; these manifesta-
tions include systemic symptoms, such as fever, arthralgia, and Raynaud’s phe-
nomenon, as seen in the antisynthetase syndrome4,6,7; cardiac arrhythmias or 
ventricular dysfunction, in relatively uncommon cases in which the affected car-
diac muscle is clinically symptomatic; and pulmonary complications, due primar-
ily to interstitial lung disease, which are reported in 10 to 40% of patients.8 The 
prevalence of interstitial lung disease, a condition that is best detected with high-
resolution computed tomography, is as high as 70% among patients with anti–his-
tidyl–transfer RNA (tRNA) synthetase (anti-Jo-1) or anti–melanoma differentiation–
From the Department of Neurology, 
Neuromuscular Division, Thomas Jeffer-
son University, Philadelphia; and Neuro-
immunology Unit, University of Athens 
Medical School, Athens. Address reprint 
requests to Dr. Dalakas at the Depart-
ment of Neurology, Neuromuscular Divi-
sion, Thomas Jefferson University, 901 
Walnut St., Philadelphia, PA 19107, or at 
 marinos . dalakas@ jefferson . edu.
N Engl J Med 2015;372:1734-47.
DOI: 10.1056/NEJMra1402225
Copyright © 2015 Massachusetts Medical Society.
Dan L. Longo, M.D., Editor
Inflammatory Muscle Diseases
Marinos C. Dalakas, M.D.
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on November 15, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;18 nejm.org April 30, 2015 1735
Inflammatory Muscle Diseases
associated protein (MDA)–5 antibodies (see the 
Glossary).6-8
Specific Clinic a l Fe at ur es
Dermatomyositis
The specific clinical features of inflammatory 
myopathies are described in Table 1 and in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org. Dermatomyositis 
is seen in both children and adults, and the early 
symptoms include distinct skin manifestations 
accompanying or preceding muscle weakness; the 
skin manifestations include periorbital heliotrope 
(blue–purple) rash with edema; erythematous rash 
on the face, knees, elbows, malleoli, neck, anterior 
chest (in a V-sign), and back and shoulders (in a 
shawl sign); and a violaceous eruption (Gottron’s 
rash) on the knuckles, which may evolve into a 
scaling discoloration.1-7,9 The lesions are photo-
sensitive and may be aggravated by ultraviolet 
radiation.6,7,9 Dilated capillary loops at the base 
of the fingernails, irregular and thickened cuti-
cles, and cracked palmar fingertips (“mechanic’s 
hands”) are characteristic of dermatomyositis.1-3 
Subcutaneous calcifications, sometimes extrud-
ing to the surface of the skin and causing ulcer-
ations and infections, may occur and are espe-
cially common among children. If the patient’s 
strength appears to be normal, the dermatomyo-
sitis may be limited to the skin (amyopathic der-
matomyositis),9 although subclinical muscle in-
volvement is frequent.1-3 In children, an early 
symptom is “misery,” defined as irritability com-
bined with a red flush on the face, fatigue, and 
a reluctance to socialize.2,3
The symptoms of dermatomyositis may over-
lap with those of systemic sclerosis and mixed 
connective-tissue disease1-7; in such cases, the typi-
cal skin rash is transient or faint. Overlap myo-
sitis is now starting to be recognized as a dis-
tinct entity; it manifests without the rash that is 
typical of dermatomyositis, with prominent patho-
logic changes in the perifascicular, interfascicular, 
and perimysial regions, and is frequently associ-
ated with antisynthetase antibodies.10 In adults, 
the risk of cancer is increased during the first 
3 to 5 years after the onset of dermatomyositis, 
with reported a frequency of 9 to 32%.11,12 The 
most common cancers are ovarian cancer, breast 
cancer, colon cancer, melanoma, nasopharyngeal 
cancer (in Asians), and non-Hodgkin’s lymphoma; 
the risk of these cancers necessitates a thorough 
annual workup in the first 3 years after disease 
onset.11,12
Polymyositis
Polymyositis is rare as a stand-alone entity and 
is often misdiagnosed; most patients whose con-
dition has been diagnosed as polymyositis have 
inclusion-body myositis, necrotizing autoimmune 
myositis, or inflammatory dystrophy.3,13 Polymyo-
sitis remains a diagnosis of exclusion and is best 
defined as a subacute proximal myopathy in adults 
who do not have rash, a family history of neuro-
muscular disease, exposure to myotoxic drugs 
(e.g., statins, penicillamine, and zidovudine), in-
volvement of facial and extraocular muscles, en-
Anti–cytosolic 5′-nucleotidase 1A (anti-cN1A, or anti-NT5C1A): Autoantibody directed against the cN1A nuclear protein 
involved in RNA processing; associated with inclusion-body myositis.
Anti–histidyl–transfer RNA synthetase (anti-Jo-1): The most common autoantibody associated with the antisynthetase 
syndrome, which consists of myopathy, fever, interstitial lung disease, Raynaud’s phenomenon, arthritis, and “me-
chanic’s hands.”
Anti–3-hydroxy-3-methylglutaryl–coenzyme A reductase (anti-HMGCR): Autoantibody directed against HMGCR, the 
pharmacologic target of statins; specific for necrotizing autoimmune myositis.
Anti–melanoma differentiation–associated protein-5 (anti-MDA-5): Autoantibody directed against a cytoplasmic RNA-
specific helicase; associated with amyopathic dermatomyositis or rapidly progressive interstitial lung disease.
Anti-Mi-2: Autoantibody directed against a nuclear DNA helicase involved in transcriptional activation; associated with 
typical skin lesions of dermatomyositis.
Anti–signal recognition particle (anti-SRP): Autoantibody directed against a polypeptide complex involved in protein 
transport to endoplasmic reticulum; specific for necrotizing autoimmune myositis.
Anti–transcriptional intermediary factor 1 γ (anti-TIF-1γ): Autoantibody involved in cell growth and differentiation; seen 
in cancer-associated dermatomyositis, along with anti–nuclear matrix protein 2 (anti-NXP-2).
Glossary
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docrinopathy, or the clinical phenotype of inclu-
sion-body myositis.1-3
Necrotizing Autoimmune Myositis
Necrotizing autoimmune myositis is a distinct 
clinicopathologic entity that occurs more frequent-
ly than polymyositis, accounting for up to 19% 
of all inflammatory myopathies.13 It can occur at 
any age but is seen primarily in adults; it starts 
either acutely, reaching its peak over a period of 
days or weeks, or subacutely, progressing steadi-
ly and causing severe weakness and very high 
creatine kinase levels.14,15 Necrotizing autoimmune 
myositis occurs alone or after viral infections, in 
association with cancer, in patients with connec-
tive-tissue disorders such as scleroderma, or in 
patients taking statins, in whom the myopathy 
continues to worsen after statin withdrawal (if 
the myopathy improves within 4 to 6 weeks after 
discontinuation of statins, it was probably caused 
by toxic effects of the drug rather than by im-
mune myopathy).3,4,6,14-16 Most patients with nec-
rotizing autoimmune myositis have antibodies 
against signal recognition particle (SRP) or against 
3-hydroxy-3-methylglutaryl–coenzyme A reductase 
(HMGCR) (see the Glossary).14-16
Inclusion-Body Myositis
Inclusion-body myositis is the most common and 
disabling inflammatory myopathy among persons 
50 years of age or older.1-5,17-23 Its prevalence, 
which was initially estimated in the Netherlands 
as 4.9 cases per million population,18 is much 
higher when adjusted for age; in two later stud-
ies in Australia and the United States, the age-
adjusted prevalence ranged from 51.3 to 70 cases 
per million.19,22 In a small chart-review study con-
ducted in one U.S. county, the estimated inci-
dence of inclusion-body myositis was 7.9 cases 
per million in the 1980s and 1990s.19 The dis-
ease starts insidiously and develops over a peri-
od of years, at times asymmetrically (i.e., it may 
start or be more severe in one extremity or on one 
side of the body), and progresses steadily, simu-
lating a late-life muscular dystrophy or slowly 
progressive motor-neuron disease.1-5 Although in-
clusion-body myositis is commonly suspected 
when a patient’s presumed polymyositis does not 
respond to therapy,3 features that can lead to an 
early clinical diagnosis include the early involve-
ment of distal muscles, especially foot extensors 
and finger flexors; atrophy of the forearms and 
quadriceps muscles; frequent falls due to quad-
riceps muscle weakness causing buckling of the 
knees; and mild facial-muscle weakness.1-5,20-23 The 
axial muscles may be affected, which results in 
camptocormia (bending forward of the spine) or 
head drop. Dysphagia occurs in more than 50% 
of the patients.23
Di agnosis
The diagnosis of the exact subtype of inflamma-
tory myopathy is based on the combination of 
clinical history, tempo of disease progression, 
pattern of muscle involvement, muscle enzyme 
levels, electromyographic findings, muscle-biopsy 
analysis, and for some conditions, the presence 
of certain autoantibodies (Table 1). Typical skin 
changes, with or without muscle weakness, indi-
cate dermatomyositis; a subacute onset of proxi-
mal myopathic weakness points to polymyositis 
or necrotizing autoimmune myositis; and slowly 
progressive proximal and distal weakness with 
selective atrophy points to inclusion-body myosi-
tis. Electromyography is diagnostically useful in 
all disease subtypes to rule out neurogenic con-
ditions and assess disease activity. Serum creatine 
kinase is elevated in all subtypes, but very high 
levels from the outset point to necrotizing auto-
immune myositis. Magnetic resonance imaging 
(MRI) is helpful for diagnosis when muscle edema 
is present or myofasciitis is suspected, as well as 
for identification of the particular muscles affected 
by atrophy in inclusion-body myositis. Muscle 
biopsy is essential for the diagnosis of polymyo-
sitis, overlap myositis, necrotizing autoimmune 
myositis, and inclusion-body myositis, as well as 
for ruling out disease mimics such as dystrophies 
or metabolic or vacuolar myopathies. Assessment 
of autoantibodies is helpful for the diagnosis of 
necrotizing autoimmune myositis and for the 
classification of distinct subtypes and their as-
sociations with systemic organ involvement, such 
as interstitial lung disease.
Among muscle-derived enzymes in serum, the 
most sensitive indicator of inflammatory myop-
athy is creatine kinase, which is elevated in pa-
tients with active disease. The highest levels, up to 
more than 50 times the upper limit of normal, 
are seen in patients with necrotizing autoimmune 
myositis, and the lowest (less than 10 times the 
upper limit of normal) are seen in patients with 
inclusion-body myositis. Although serum levels 
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of creatine kinase usually parallel disease activ-
ity, they can be normal or only slightly elevated 
in patients with active dermatomyositis, overlap 
myositis, or active inclusion-body myositis. Along 
with creatine kinase, aspartate aminotransferase 
and alanine aminotransferase levels are also el-
evated, a sign that is sometimes erroneously in-
terpreted as indicating liver disease and that leads 
to an investigation with a liver biopsy instead of 
a muscle biopsy. Serum aldolase levels may be 
also elevated, especially if the fascia is involved.
Electromyography can show myopathic motor-
unit potentials (short-duration, low-amplitude 
polyphasic units on voluntary activation) and in-
creased spontaneous activity with fibrillations, 
complex repetitive discharges, and positive sharp 
waves. These findings are useful in determining 
whether the myopathy is active or chronic and in 
ruling out neurogenic disorders, but they cannot 
be used for differentiating inflammatory myopa-
thies from toxic or dystrophic myopathies.1-5
MRI can be used to identify edema, inflam-
mation in muscle or fascia, fatty infiltration, fi-
brosis, or atrophy. It is useful for assessing the 
extent and selectivity of muscle involvement, es-
pecially in cases of inclusion-body myositis; for 
identifying disease activity; and for guiding the 
selection of the muscle with the greatest degree 
of inflammation to biopsy.3,4,6,7
Examination of muscle-biopsy samples reveals 
features distinct to each disease subtype, and 
although the results are not always typical or 
specific, it remains the most important diagnos-
tic tool. Muscle biopsy is most useful when the 
biopsy site is properly chosen (i.e., in a muscle 
that does not have clinical signs of advanced or 
end-stage disease but is also not minimally af-
fected), the specimen is processed at an experi-
enced laboratory, and the findings are inter-
preted in the context of the clinical picture.1-3,24,25
In dermatomyositis, the inflammation is peri-
vascular and is most prominently located in the 
interfascicular septae or the periphery of the 
fascicles. The muscle fibers undergo necrosis and 
phagocytosis — often in a portion of a muscle 
fasciculus or the periphery of the fascicle — 
owing to microinfarcts that lead to hypoperfu-
sion and perifascicular atrophy.1-5 Perifascicular 
atrophy, which is characterized by layers of atro-
phic fibers at the periphery of the fascicles, often 
with perivascular and interfascicular infiltrates, 
is diagnostic of dermatomyositis (or of overlap 
myositis, when the skin changes are absent or 
transient)1-5,10,24,25 (Fig. 1A).
In polymyositis and inclusion-body myositis, 
the inflammation is perivascular and is most 
typically concentrated in multiple foci within the 
endomysium; it consists predominantly of CD8+ 
T cells invading healthy-appearing, nonnecrotic 
muscle fibers expressing major histocompatibil-
ity complex (MHC) class I antigen (normal mus-
cle fibers do not express this antigen) (Fig. 2A, 
2C, and 2D). The finding of MHC expression and 
Figure 1 (facing page). Dermatomyositis: A Comple-
ment-Mediated Microangiopathy.
Panel A shows a cross-section of a hematoxylin and 
eosin–stained muscle-biopsy sample with classic der-
matomyositis perifascicular atrophy (layers of atrophic 
fibers at the periphery of the fascicle [arrows]) and 
some inflammatory infiltrates. Panel B shows the de-
position of complement (membranolytic attack com-
plex, in green) on the endothelial cell wall of endo-
mysial vessels (stained in red with Ulex europaeus 
lectin), which leads to destruction of endothelial cells 
(shown in orange, indicating the superimposition of 
red and green). Consequently, in the muscles of pa-
tients with dermatomyositis (shown in Panel C), as 
compared with a myopathic control (Panel D), the den-
sity of the endomysial capillaries (in yellow–red) is re-
duced, especially at the periphery of the fascicle, with 
the lumen of the remaining capillaries dilated in an ef-
fort to compensate for the ischemic process.1,2 Panel E 
shows a schematic diagram of a proposed immuno-
pathogenesis of dermatomyositis. Activation of com-
plement component 3 (C3) (probably triggered by anti-
bodies against endothelial cells) is an early event 
leading to the formation of C3b, C3bNEO, and mem-
brane attack complexes (MACs), which are deposited 
on the endothelial cell wall of the endomysial capillar-
ies; this results in the destruction of capillaries, isch-
emia, or microinfarcts, which are most prominent in 
the periphery of the fascicles, as well as in perifascicu-
lar atrophy. Cytokines released by activated comple-
ment lead to the activation of CD4+ T cells, macro-
phages, B cells, and CD123+ plasmacytoid dendritic 
cells; enhance the expression of vascular-cell adhesion 
molecules (VCAMs) and intercellular adhesion molecule 
(ICAM) on the endothelial cell wall; and facilitate lym-
phoid cell transmigration to endomysial tissue through 
the action of their integrins, late activation antigen 
(VLA)–4, and lymphocyte function–associated antigen 
(LFA)–1, which bind VCAM-1 and ICAM-1. The perifas-
cicular regions contain fibers that are in a state of re-
modeling and regeneration (expressing TGF-β, NCAM, 
and Mi-2), cell stress (expressing heat shock protein 70 
[HSP70] and HSP90), and immune activation (express-
ing major histocompatibility complex [MHC] class I an-
tigen, chemokines, and STAT1), as well as molecules as-
sociated with innate immunity (such as MxA, ISG15, 
and retinoic acid–inducible gene 1 [RIG-1]).
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CD8+ T cells (termed the MHC–CD8 complex) is 
useful for confirming the diagnosis and for rul-
ing out disorders with nonimmune inflamma-
tion, as seen in some muscular dystrophies.2,3,5,17,25
In necrotizing autoimmune myositis, there are 
abundant necrotic fibers invaded or surrounded 
by macrophages (Fig. 2E and 2F). Lymphocytic 
infiltrates are sparse, and MHC class I up-regu-
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lation is often prominent beyond the necrotic fi-
bers.3,4,6,14,25 Necrotizing autoimmune myositis is 
most often mediated by specific antibodies against 
SRP or HMGCR (see the Glossary), often with 
complement deposits on capillaries.15,16
Inclusion-body myositis has all the inflamma-
tory features of polymyositis, including the CD8–
MHC complex, but in addition has chronic myo-
pathic changes with increases in connective tissue 
and in the variability in fiber size, autophagic 
vacuoles that have walls lined internally with 
material that stains bluish-red with hematoxylin 
and eosin or modified Gomori trichrome (Fig. 2B), 
“ragged-red” or cytochrome oxidase–negative fi-
bers representing abnormal mitochondria, and 
congophilic amyloid deposits next to the vacu-
oles, which are best visualized with crystal violet 
or fluorescent optics.3-5,20-23 Electron microscopy 
shows tubulofilaments 12 to 16 nm in diameter 
next to the vacuoles.20 In up to 30% of patients 
with the typical clinical inclusion-body myositis 
phenotype, vacuoles or amyloid deposits are not 
found in the muscle-biopsy sample and only in-
flammation is seen, which leads to an erroneous 
diagnosis of polymyositis.26 Such patients have 
“clinical inclusion-body myositis” diagnosed on 
the basis of clinicopathologic correlation.27,28 Data-
driven criteria confirm that finger-flexor or quad-
riceps weakness, inflammation around nonne-
crotic fibers with MHC class I expression, and 
cytochrome oxidase–negative fibers, even without 
vacuoles, are specific for the diagnosis of clini-
cal inclusion-body myositis.27,28
Autoantibodies directed against nuclear RNAs 
or cytoplasmic antigens are detected in up to 60% 
of patients with inflammatory myopathies,6,7,16,29 
depending on the case series and the method of 
detection used. Although the pathogenic role of 
the antibodies is unclear, some appear to be spe-
cific for distinct clinical phenotypes and HLA-DR 
genotypes. These antibodies include those against 
aminoacyl tRNA synthetases (ARSs), which are 
detected in 20 to 30% of patients.7,16 Among the 
eight different ARSs that have been identified, 
anti-Jo-1, the most widely commercially available 
antibody, accounts for 75% of all antisynthetas-
es associated with the antisynthetase syndrome. 
This syndrome is characterized by myositis with 
prominent pathologic changes at the periphery 
of the fascicles and the perimysial connective 
tissue,10 interstitial lung disease, arthritis, Rayn-
aud’s phenomenon, fever, and mechanic’s hands.7 
In one rare case, γδ T cells were found to recog-
nize ARS, which provided the first pathogenic link 
between ARS and T-cell–mediated immunity.30
Necrotizing autoimmune myositis–specific 
anti bodies are directed against the translational 
transport protein SRP or against HMGCR, the 
pharmacologic target of statins.15,16 Anti-HMGCR, 
seen in 22% of persons with necrotizing autoim-
mune myositis, regardless of statin use, correlates 
Figure 2 (facing page). Main Inflammatory Features  
of Polymyositis, Inclusion-Body Myositis, and Necrotiz-
ing Autoimmune Myositis and a Proposed Immuno-
pathogenic Scheme for Polymyositis and Inclusion-
Body Myositis.
Panels A and B show cross-sections of hematoxylin 
and eosin–stained muscle-biopsy samples from a pa-
tient with polymyositis (Panel A) and a patient with in-
clusion-body myositis (Panel B), in which scattered in-
flammatory foci with lymphocytes invading or 
surrounding healthy-appearing muscle fibers are visi-
ble. In inclusion-body myositis, there are also chronic 
myopathic features (increases in connective tissue and 
atrophic and hypertrophic fibers) and autophagic vacu-
oles with bluish-red material, most prominent in fibers 
not invaded by T cells (arrow). In both polymyositis 
and inclusion-body myositis, the cells surrounding or 
invading healthy fibers are CD8+ T cells, stained in 
green with an anti-CD8+ monoclonal antibody (Panel 
C); also visible is widespread expression of MHC class 
I, shown in green in Panel D, even in fibers not invad-
ed by T cells. In contrast, in necrotizing autoimmune 
myositis (a cross-section stained with trichrome is 
shown in Panel E), there are scattered necrotic fibers 
invaded by macrophages (Panel F), which are best vi-
sualized with an acid phosphatase reaction (in red). 
Panel G shows a proposed mechanism of T-cell–medi-
ated muscle damage in polymyositis and inclusion-
body myositis. Antigen-specific CD8+ cells, expanded 
in the periphery and subsequently in the endomysium, 
cross the endothelial cell wall and bind directly to aber-
rantly expressed MHC class I on the surface of muscle 
fibers through their T-cell receptors, forming the 
MHC–CD8 complex. Up-regulation of costimulatory 
molecules (BB1 and ICOSL) and their ligands (CD28, 
CTLA-4, and ICOS), as well as ICAM-1 or LFA-1, stabi-
lizes the synaptic interaction between CD8+ cells and 
MHC class I on muscle fibers. Regulatory Th17 cells 
play a fundamental role in T-cell activation. Perforin 
granules released by the autoaggressive T cells medi-
ate muscle-fiber necrosis. Cytokines, such as 
interferon-γ, interleukin-1, and tumor necrosis factor 
(TNF) released by the activated T cells, may enhance 
MHC class I up-regulation and T-cell cytotoxicity. Acti-
vated B cells or plasmacytoid dendritic cells are clonal-
ly expanded in the endomysium and may participate in 
the process in a still-undefined role, either as antigen-
presenting cells or through the release of cytokines 
and antibody production.
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with creatine kinase levels and strength.31 Derma-
tomyositis-associated antibodies include anti-Mi-2, 
which is associated with the typical skin lesions; 
anti-MDA-5, which is associated primarily with 
amyopathic dermatomyositis or interstitial lung 
disease4,6,16; and anti–transcriptional intermedi-
ary factor 1γ (anti-TIF-1γ) and anti–nuclear matrix 
protein 2 (anti-NXP-2), which are usually present 
in patients with cancer-associated adult derma-
tomyositis,29 although their presence is influ-
enced by geographic, racial, and genetic factors. 
Anti–cytosolic 5′-nucleotidase 1A (anti-cN1A) is 
detected in 60 to 70% of patients with inclusion-
body myositis,32,33 although the degree of sensi-
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tivity and specificity varies according to the meth-
od of detection used, and indicates B-cell activation.
Pathol o gic Mech a nisms
Immunopathology
The causes of inflammatory myopathies are un-
known, but an autoimmune pathogenesis is 
strongly implicated. In dermatomyositis, comple-
ment C5b-9 membranolytic attack complex is acti-
vated early (before the destruction of muscle fi-
bers is evident) and deposited on the endothelial 
cells, leading to necrosis, reduction of the density 
of endomysial capillaries, ischemia, and muscle-
fiber destruction resembling microinfarcts1-6,24,25,34; 
the remaining capillaries have dilated lumens to 
compensate for the ischemia2,3,25 (Fig. 1A through 
1D). The residual perifascicular atrophy reflects 
the endofascicular hypoperfusion, which is most 
prominent at the periphery of the fascicles.2,3,24,25 
The activation of membrane attack complex, 
presumably by antibodies, triggers the release of 
proinflammatory cytokines, up-regulates adhe-
sion molecules on endothelial cells, and facili-
tates migration of activated lymphocytes, including 
B cells, CD4+ T cells, and plasmacytoid dendritic 
cells, to the perimysial and endomysial spaces 
(Fig. 1E). Innate immunity also plays a role that is 
based on increased expression of type I interferon–
inducible proteins in the perifascicular region,35 
an area where other inflammatory, degenerative, 
or regenerative molecules are also overexpressed 
(Fig. 1E); it remains to be determined whether the 
effect of innate immunity is caused by retinoic 
acid–inducible gene 1 signaling in response to 
local signals from the damaged fibers, which 
leads to autoamplification of perifascicular in-
flammation by activating interferon-β and MHC 
class I36 (Fig. 1E). In juvenile dermatomyositis, 
maternal chimeric cells may contribute to the 
pathogenesis of the disease.37
In polymyositis and inclusion-body myositis, 
CD8+ cytotoxic T cells surround and invade 
healthy-appearing, nonnecrotic muscle fibers that 
aberrantly express MHC class I (Fig. 2A through 
2D).38,39 MHC class I expression, which is absent 
from the sarcolemma of normal muscle fibers, is 
probably induced by cytokines secreted by acti-
vated T cells.40,41 The CD8–MHC class I complex 
is characteristic of polymyositis and inclusion-
body myositis, and its detection aids in confirm-
ing the histologic diagnosis.2-5,25 The CD8+ T cells 
contain perforin granules directed toward the 
surface of the muscle fibers, which cause myo-
necrosis on release.42 Analysis of T-cell–receptor 
molecules expressed by the infiltrating CD8+ 
T cells reveals clonal expansion of T-cell–recep-
tor chains and conserved sequences in the anti-
gen-binding region, which suggests an antigen-
driven T-cell response.43,44 This is further supported 
by the expression of costimulatory molecules and 
up-regulation of adhesion molecules, chemokines, 
and cytokines45-47 (Fig. 2G). Th17 and regulatory 
T cells participate in the immune process.48 The 
up-regulation and overload of MHC class I may 
also cause glycoprotein misfolding, which stress-
es the endoplasmic reticulum of the myofibers.49 
B-cell activation also occurs, most prominently 
in inclusion-body myositis50 (although it is un-
clear whether the muscle can sustain germinal 
center formations), in which anti-cN1A autoan-
tibodies are also detected (see the Glossary).
The factors that trigger inflammatory muscle 
diseases remain unknown. Genetic risk factors 
regulating immune responses against undefined 
environmental agents have been proposed.7 
Genetic interactions are supported by the associa-
tions between HLA-DRB1*03 and anti-Jo-1, be-
tween HLA-DRB1*11:01 and anti-HMGCR–pos-
itive necrotizing autoimmune myositis, and 
between HLA-DRB1*03:01 and HLA-DRB1*01:01 
and inclusion-body myositis.51 Viruses may be 
responsible for disrupting immune tolerance, but 
attempts to amplify viruses — including coxsacki-
eviruses, influenza virus, paramyxoviruses (includ-
ing mumps virus), cytomegalovirus, and Epstein-
Barr virus — from the muscles have failed.1-5 
The best evidence for a viral connection involves 
retroviruses, because polymyositis or inclusion-
body myositis develops in people infected with 
human immunodeficiency virus (HIV) or human 
T-cell lymphotropic virus I.52,53 However, retrovi-
ral antigens are detected only in endomysial 
macrophages and not within the muscle fibers. 
The autoinvasive T cells are clonally driven, and 
some are retroviral-specific.52 HIV-associated poly-
myositis and HIV-associated inclusion-body my-
ositis should be distinguished from a toxic mi-
tochondrial myopathy induced by antiretroviral 
drugs, which improves when the drugs are dis-
continued.54
Degenerative Component of Inclusion-Body 
Myositis
Inclusion-body myositis is a complex disorder be-
cause, in addition to the autoimmunity compo-
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nent, there is an important degenerative compo-
nent, highlighted by the presence of congophilic 
amyloid deposits within some fibers.20-22 Similar 
to what is seen in Alzheimer’s disease, these 
deposits immunoreact against amyloid precursor 
protein, amyloid-β42, apolipoprotein E, α-synuclein, 
presenilin, ubiquitin, and phosphorylated tau, 
which indicates the presence of protein aggrega-
tion.20 Deposits of TDP43, a DNA-binding pro-
tein aberrantly translocated from the nuclei to the 
cytoplasm, and p62, a shuttle protein that trans-
ports polyubiquitinated proteins, detected within 
the muscle fibers with the use of immunostain-
ing, have been advocated as diagnostic markers.20,55
In vitro evidence suggests that amyloid-β42 and 
its oligomers are involved in the pathway of in-
tracellular toxicity,20 but it remains unclear how 
these proteinaceous aggregates, which are also 
seen in other vacuolar myopathies, induce an in-
flammatory and degenerative myopathy and what 
triggers disease, inflammation, or protein aggre-
gation.21 Laser microdissection of T-cell–invaded 
fibers in comparison with noninvaded or vacuolat-
ed fibers has revealed differential up-regulation 
Figure 3. Proposed Mechanisms in Inclusion-Body Myositis.
Shown is a hypothetical schematic diagram of the pathogenesis of inclusion-body myositis, highlighting the interaction between the 
long-standing chronic inflammatory process and degeneration, which leads to cell stress and deposits of β-amyloid precursor protein, 
amyloid-β42, and misfolded proteins similar to the ones seen in neuroinflammatory disorders such as Alzheimer’s disease. Therefore, 
inclusion-body myositis can be considered to be a peripheral model of neuroinflammation. The factors that trigger the disease are un-
clear, but viruses, muscle aging, protein misregulation (such as abnormal proteostasis), impaired autophagy, and HLA genotypes may 
play a role, either alone or in combination. Whether the primary event is inflammatory or degenerative is highly debated and remains 
unclear.
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of inflammatory signaling, such as interferon-γ–
receptor signaling.56 Compelling evidence suggests 
that aging, abnormal proteostasis (the network 
controlling proteins),20 impaired autophagy, cell 
stress induced by MHC class I or nitric oxide,21,57 
long-standing inflammation, and proinflam-
matory cytokines such as interferon-γ and 
interleukin-1β57,58 may cumulatively trigger or en-
hance degeneration, leading to further accumu-
lation of stressor molecules and misfolded pro-
teins59 (Fig. 3).
Tr e atmen t of Der m at om yosi tis, 
Polym yosi tis,  a nd Necro tizing 
Au t oimmune M yosi tis
Strategies for the treatment of the inflammatory 
myopathies are described in Table 2. Oral pred-
nisone administered once daily after breakfast at 
a dose of 1 mg per kilogram of body weight, up 
to 100 mg per day, is the first-line drug for the 
treatment of dermatomyositis, polymyositis, and 
necrotizing autoimmune myositis; this choice of 
drug is based on experience but not on controlled 
trials.1-6,60,61 Some clinicians prefer to add an im-
munosuppressant agent from the outset.6,61 In 
patients with rapidly worsening disease, it is pref-
erable to administer intravenous methylprednis-
olone at a dose of 1000 mg per day for 3 to 5 days 
before starting treatment with oral glucocorti-
coids. After 3 to 4 weeks, prednisone is tapered, 
as dictated by the response of the disease to 
therapy, preferably by a switch from a daily dose 
to doses on alternate days60; however, if the ob-
jective signs of increased strength and ability to 
perform activities in daily living are absent at 
that time, tapering is accelerated so that treat-
ment with a next agent can be started. A tactical 
error is the practice of “chasing” the creatine 
kinase level as a sign of response, especially in 
patients who report a sense of feeling better but 
not necessarily of feeling stronger. When the 
strength improves, the serum creatine kinase level 
drops, but a decrease in creatine kinase alone is 
not a sign of improvement.60
For patients in whom glucocorticoids produce 
a response, azathioprine, mycophenolate mofetil, 
methotrexate, or cyclosporine can be used em-
pirically for glucocorticoid sparing.2-4,6,60,61 When 
interstitial lung disease is a coexisting condition, 
Scenario
Treatment for Dermatomyositis, Polymyositis, 
and Necrotizing Autoimmune Myositis
Treatment for Inclusion-Body 
Myositis
Initiation of therapy
New-onset disease Prednisone (1 mg per kilogram, up to 100 mg 
per day) for 4–6 weeks; taper to alternate 
days
Physical therapy; participation 
in research trial
When weakness at onset is 
severe or rapidly worsening
Intravenous glucocorticoids (1000 mg per day) 
for 3 to 5 days, then switch to oral regimen
Not applicable
For glucocorticoid sparing, if the 
patient’s condition 
responds to glucocorticoids
Azathioprine, methotrexate, mycophenolate, 
cyclosporine*
Not applicable†
If response to glucocorticoids is 
insufficient
Intravenous immune globulin (2 g per kilogram 
in divided doses over a period of 2 to 5 con-
secutive days)
Not applicable‡
If response to glucocorticoids and 
intravenous immune globu-
lin is insufficient
Reevaluate and reconsider diagnosis; initiate 
treatment with rituximab§ if diagnosis is re-
confirmed, recommend participation in a re-
search trial¶ if disease does not respond to 
rituximab
Participation in research trial
*  The use of these agents is based on experience but not on controlled studies. Azathioprine can be given at a dose of up 
to 3 mg per kilogram, methotrexate at a dose of up to 20 mg per week, mycophenolate at a dose of 2000 to 3000 mg 
per day, and cyclosporine at a dose of up to 300 mg daily. Intravenous cyclophosphamide (0.8 to 1 g per square meter 
of body surface area) and oral tacrolimus (4–8 mg per day) may help patients with interstitial lung disease.
†  All glucocorticoid-sparing agents are ineffective, either alone or in combination.
‡  In some patients, the dysphagia responds to intravenous immune globulin.
§  Efficacy has not been established with a controlled study, but the evidence of efficacy is compelling.
¶  Candidate agents include eculizumab, alemtuzumab, tocilizumab (anti–interleukin-6), anti–interleukin-17, and anti–
interleukin-1β.
Table 2. Treatment of Inflammatory Myopathies: A Step-by-Step Approach.
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cyclophosphamide or tacrolimus may be help-
ful.6,60,62 In patients with dermatomyositis, topi-
cal glucocorticoids or calcineurin inhibitors and 
sunlight avoidance are recommended. When glu-
cocorticoids fail to induce remission or in severe 
and rapidly progressive cases, intravenous im-
mune globulin therapy (2 g per kilogram in di-
vided doses over a period of 2 to 5 consecutive 
days) is appropriate.2-4,6,60,61 In a double-blind 
study, intravenous immune globulin was found to 
be effective in the treatment of refractory derma-
tomyositis63; monthly infusions may be required 
to maintain remission.60,63 In open-label trials, 
intravenous immune globulin has also appeared 
to be effective in the treatment of polymyositis 
and necrotizing autoimmune myositis.6,60 Subcuta-
neous immune globulin has appeared to sustain 
remission in small-scale, uncontrolled studies.64
If the disease has not responded to glucocor-
ticoids and intravenous immune globulin, the 
patient should be reevaluated, and if there are 
diagnostic uncertainties, a repeat muscle biopsy 
should be considered. If the diagnosis is recon-
firmed, biologic agents that have been approved 
for the treatment of other immune diseases may 
be considered as experimental treatment options.60 
These include rituximab (an anti-CD20 antibody), 
which at a dose of 2 g (divided into two infu-
sions 2 weeks apart) seems effective in some 
patients with dermatomyositis, polymyositis, or 
necrotizing autoimmune myositis. In a placebo-
controlled study involving 200 patients, at week 
8 there was no difference between the placebo 
group and the rituximab group, and on the basis 
of the study design, the results were not signifi-
cant; however, at week 44, when all the patients 
had received rituximab, 83% met the definition 
of improvement.65 Patients with anti-Jo-1, anti-
Mi-2, or anti-SRP antibodies seem more likely to 
have a response.66,67 Tumor necrosis factor inhibi-
tors (infliximab, adalimumab, and etanercept) are 
ineffective and may worsen or trigger disease.68 
Other biologics that may be considered as experi-
mental treatment include alemtuzumab, which 
is reportedly effective in polymyositis69; anti-com-
plement C3 (eculizumab), which is effective in 
complement-mediated diseases and may be ef-
fective for the treatment of dermatomyositis and 
necrotizing autoimmune myositis; anti–interleu-
kin-6 (tocilizumab)70 and anti–interleukin-1 re-
ceptor (anakinra),71 which have been effective in 
anecdotal cases; anti–interleukin-17; and anti–
interleukin-1β (gevokizumab), which is being 
evaluated in an ongoing trial (EudraCT number, 
2012-005772-34). Overall, the long-term outcome 
of inflammatory myopathies has substantially 
improved, with a 10-year survival rate of more 
than 90%.72
Tr e atmen t of Inclusion-Body 
M yosi tis
Because of T-cell–mediated cytotoxic effects and 
the enhancement of amyloid-related protein ag-
gregates by proinflammatory cytokines in pa-
tients with inclusion-body myositis,21,57,58 immu-
nosuppressive agents have been tried as treatment 
for this disease subtype, but all have failed, 
probably because the disease starts long before 
patients seek medical advice, when the degen-
erative cascade is already advanced.60 Glucocorti-
coids, methotrexate, cyclosporine, azathioprine, 
and mycophenolate are ineffective, and although 
some patients may initially have mild subjective 
improvements when treated with one of these 
agents,60,61 no long-term benefit is achieved.73 In-
travenous immune globulin has been found to be 
ineffective in controlled trials but may transiently 
help some patients, especially those with dyspha-
gia.74,75 Alemtuzumab may provide short-term sta-
bilization,76 but a controlled study is needed. 
Treatment with anakinra has also not been suc-
cessful.77 Trials targeting muscle-inhibiting TGF-β 
molecules or muscle growth factors are in prog-
ress. Bimagrumab, an antibody that inhibits the 
signaling of a TGF-β superfamily receptor, was 
shown in a small-scale study to increase muscle 
volume after 8 weeks,78 which has prompted an 
ongoing controlled study (ClinicalTrials.gov num-
ber, NCT01925209). A small, controlled, proof-of-
concept study of arimoclomol (ClinicalTrials.gov 
number, NCT00769860), an agent that up-regu-
lates heat shock protein response and attenuates 
cell stress, has been completed; the drug had an 
acceptable adverse-event profile, but whether there 
were clinically meaningful benefits is still un-
clear.79
At present, symptomatic therapies are the 
best option. For life-threatening dysphagia that 
is not responding to intravenous immune globu-
lin, cricopharyngeal dilation or myotomy may be 
considered. As with all inflammatory myopa-
thies, nonfatiguing resistance exercises and oc-
cupational and rehabilitation therapies are use-
ful to improve ambulation, prevent falling, avoid 
disuse atrophy, and prevent joint contractures.80 
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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Although the life expectancy of patients with 
inclusion-body myositis is normal, most patients 
with end-stage disease require assistive devices 
such as a cane, walker, or wheelchair.23
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